View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Analysis
February 18, 2022

IQVIA tops list of pharma companies with big data mentions in filings

Big data mentions within filings of pharma industry companies were 64% higher between October 2020 and September 2021 than in 2016.

By Data Journalism Team

The CRO IQVIA referred to big data the most between October 2020 and September 2021 of the 50 biggest employers in the pharmaceutical industry. GlobalData identified 27 big data-related sentences in the company’s filings – 0.5% of all sentences.

The CRO PRA Health Sciences mentioned big data the second most – the issue was referred to in 0.4% of sentences in the company’s filings. Other top employers with high big data mentions included Novartis, Johnson & Johnson, and Merck.

This analysis provides an approximate indication of which companies are focusing on big data and how important the issue is considered within the pharma industry, but it also has limitations and should be interpreted carefully. For example, a company mentioning big data more regularly is not necessarily proof that they are utilising new techniques or prioritising the issue, nor does it indicate whether the company’s ventures into big data have been successes or failures.

GlobalData also categorises big data mentions by a series of subthemes. Of these subthemes, the most commonly referred to topic in the third quarter of 2021 was ‘data analytics’, which made up 89% of all big data subtheme mentions by pharmaceutical companies.

That said, mentions of big data within the filings of companies in the pharmaceutical industry were 64% higher between October 2020 and September 2021 than in 2016, according to the latest analysis of data from GlobalData.

When pharmaceutical companies publish annual and quarterly reports, ESG reports and other filings, GlobalData analyses the text and identifies individual sentences that relate to disruptive forces facing companies in the coming years. Big data is one of these topics - companies that excel and invest in these areas are thought to be better prepared for the future business landscape and better equipped to survive unforeseen challenges.

To assess whether big data is featuring more in the summaries and strategies of pharmaceutical companies, two measures were calculated. Firstly, we looked at the percentage of companies which have mentioned big data at least once in filings during the past twelve months - this was 70% compared to 54% in 2016. Secondly, we calculated the percentage of total analysed sentences that referred to big data.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU